In January I wrote about a promise: that by mid-2026, Medicare would cover obesity medication for the first time in its sixty-year history, at a $50 monthly copay. I said then that the criteria being written would matter more than the press conference, and that the real report would come from the pharmacy counter in July.
It is July. This is that report, or as much of one as the early evidence allows.
The coverage is live. Patients who qualify — the rules key on body-mass index plus related conditions, and on which plan a person carries — are filling prescriptions that would have cost them four figures a month two years ago, for fifty dollars. Pharmacists describe a specific scene repeating across the country: an older patient asking the price twice, certain the first answer was a mistake. Sixty years of "weight is not a medical benefit" ended not with a law but with a benefits update, and for the people on the right side of the criteria, it is working the way coverage is supposed to work.
The rest of the report is about the sorting.
Qualification is doing what qualification does. Two patients with the same weight and the same doctor can get different answers because of plan type, paperwork, or one diagnosis code. The clinics that serve wealthier patients have staff who fight coverage denials for a living. The clinics that serve everyone else mostly don't. Early utilization is running visibly higher in exactly the places you would guess, which means the benefit is currently reaching the covered more than the burdened. That pattern is not a scandal; it is the default behavior of every new benefit ever launched. It becomes a scandal only if it is still true in three years.
The appointment bottleneck arrived on schedule. A benefit is an unlock, not a doctor. Primary care in much of the country is booked out for months, and starting these medicines responsibly involves visits, monitoring, and follow-up. The patients navigating that maze most easily are, again, the ones with the most practice navigating mazes.
And the fiscal argument has begun, as it had to. Covering a drug this popular for a population this large is expensive in year one, and the savings — fewer heart attacks, fewer joint replacements, less diabetes — arrive on a decade's delay, mostly to a different line of the budget. Every actuarial fight over this benefit for the rest of the decade will be a fight between those two clocks. Patients live on the first clock. Budgets are written on the second.
Here is what I keep coming back to. For sixty years, American health policy drew a line through one condition and called treating it a lifestyle choice. The line was never medical; the biology was settled long before the coverage was. What changed was cost, politics, and the sheer number of people affected — two in five adults, at last count, which is a lot of voters for a "lifestyle choice."
The fifty-dollar copay is the sound of a system conceding, decades late, that a disease was a disease. The concession is real. The sorting of who benefits from it has just begun, and the sorting is the story my desk will keep filing — from the counter, where a woman in her seventies is asking the price a second time, and this month, at least, the answer holds.
